Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.
about
Discovery and development of Moxalactam (6059-S): the chemistry and biology of 1-oxacephemsClinical evaluation of cefotaxime for therapy of lower respiratory tract infections.A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilliClinical evaluation of moxalactam.Clinical efficacy of cefotaxime in serious infections.Clinical experience with Moxalactam in the treatment of pseudomonal and nonpseudomonal infections.In vitro activity of new beta-lactam antibiotics and other antimicrobial drugs against anaerobic isolates from obstetric and gynecological infections.Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.The nonprophylactic role of cephalosporins in obstetrics and gynecologySusceptibility of anaerobic bacteria to nine antimicrobial agents and demonstration of decreased susceptibility of Clostridium perfringens to penicillin.Biliary excretion of moxalactam.In vitro activity of MK0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides spp.Comparative in vitro activity of new beta-lactam antibiotics against anaerobic bacteria.Mechanism of action, antimicrobial activity, pharmacology, adverse effects, and clinical efficacy of cefotaxime.Comparative in vitro activity of ceftriaxone against anaerobic bacteria.
P2860
Q28263083-6C3C774C-C85B-4BFC-8D2A-7F380AA9BEE9Q30451377-C6D1933B-DB86-4761-A7DA-B319DEF2CF25Q34707883-EA763E76-3F26-43AB-BDA1-C7EE7CB22EB3Q35668711-472D0BDD-A86D-410B-897E-EAA245BD2E9FQ35670939-147424C5-4A0B-493B-9EE7-35C2E0C5C812Q35673235-BB70E79D-5E39-42C1-BB59-6F1A91566E24Q35674991-1CAD71C3-D2CA-4191-9B95-DC23B16FDA4BQ35719143-2BB66A59-884B-441E-A013-30B362241014Q35761288-F338850C-D3C8-4ADC-8D80-5ECF5ACB4BA0Q35876845-47B1B21F-A213-4E9F-8D98-EB7BFAF33161Q39854364-343C4416-2B62-4352-BD44-1837445B81A4Q39855579-CBC3590E-ECAA-4BDD-BAF2-CE7C0A22FD46Q39855832-AF459336-2904-4BC3-9F55-67596DD48E5EQ39856001-2B5B9AC4-78D9-4210-B21E-82BB52E6BE89Q40134639-46031CED-239E-43C8-8E29-2DB0FC9E7A4DQ42926858-B5E6E09E-CAA0-4CA8-93AE-7B681BD609AA
P2860
Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.
description
1980 nî lūn-bûn
@nan
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
1980年论文
@zh
1980年论文
@zh-cn
name
Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.
@en
type
label
Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.
@en
prefLabel
Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.
@en
P2093
P2860
P356
P1476
Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.
@en
P2093
Alexander GA
Crawford SA
Jorgensen JH
P2860
P304
P356
10.1128/AAC.17.5.901
P407
P577
1980-05-01T00:00:00Z